Dimension Inx, a Chicago "biomaterials" startup developing 3D-printed medical implants, has raised new funding from investors.
The startup said today it closed on $12 million in a round led by Prime Movers Lab, with participation from KdT Ventures, Revolution's Rise of the Rest Seed Fund, Solas BioVentures, Portal Innovation Ventures and Alumni Ventures.
Dimension Inx last raised $3.2 million in 2020. Since its launch in 2017, the startup has raised $17.6 million.
The company designs, develops and manufactures 3D-printed implants that can repair human tissue and organs using technology that is based on research developed at Northwestern University. Dimension Inx's initial products are primarily used in reconstructive surgery.
The startup recently received U.S. Food & Drug Administration approval for its first product, CMFlex, a 3D-printed regenerative bone graft used in facial bone reconstructions. It is made with calcium phosphate, a material that mirrors the body's own bones.
Dimension Inx declined to disclose clients or revenue figures.
The company's CEO is Dr. Caralynn Nowinski Collens, who joined Dimension Inx in 2019 after serving as the head of federally funded research center UI Labs.
"Our approach has always focused on the entire tissue microenvironment," Nowinski Collens said in a statement. "If we provide the right blueprint, we make it possible to recruit the body's natural strengths and accelerate the repair, regeneration, and ultimately, restoration of critical body function."
The new financing will help Dimension Inx expand its manufacturing capabilities and double its team of 14 within 18 to 24 months. Dimension Inx has offices at the Illinois Institute of Technology's tech incubator and Portal Innovations, a landlord and investor for life sciences companies.
